We have found, in previous studies in vitro using skeletal derived cell cultures, that mid-region fragments of human parathyroid hormone (hPTH) stimulate [3H]thymidine incorporation into DNA and increase the specific activity of the brain-type isoenzyme of creatine kinase (CK). These changes occurred without an increase in cyclic AMP formation which is linked to bone resorption. In this study, we found that the mid-region fragment hPTH-(28-48) stimulated CK activity in diaphysis, epiphysis and kidney in a time-and dose-dependent manner, parallel to the effects of the whole molecule bovine (b)PTH-(1-84) and the fully active fragment hPTH-(1-34). The increase caused by hPTH-(28-48) at a dose of 1.25,ug/rat was not less than the 2-fold increase caused by a roughly equimolar concentration of bPTH-(1-84). A significant increase was reached at 1 h after intraperitoneal injection in all cases. All three sequences of PTH caused an increase in [3H]thymidine incorporation into DNA in diaphysis and epiphysis, but not in kidney, 24 h after injection. A fragment further towards the C-terminal, hPTH-(34-47), was inactive compared with an equimolar concentration of the fragment hPTH-(25-39), which stimulated both CK activity and DNA synthesis. These results in vivo are in line with previous findings in vitro; they provide further support for the suggestion that mid-region fragments of the PTH molecule could be used to induce bone formation without incurring the deleterious effect of bone resorption.
INTRODUCTION
Parathyroid hormone (PTH) has been shown to stimulate both formation [1] and resorption [2] of bone; the result of prolonged PTH treatment in vivo is an increase in bone turnover [3, 4] . However, specific binding of PTH can be demonstrated only in osteoblasts [5] and osteoclast precursor cells [6] , but not in mature osteoclasts. PTH has been shown to have a variety of actions in vitro, such as enhancement of cyclic AMP production [7] and cyclic AMP-dependent protein kinase activity [8] , induction of changes in cell shape [9] , stimulation of plasminogen activator [10] , inhibition of collagen synthesis [11] , suppression of alkaline phosphatase activity [12] , and stimulation of cell proliferation [13, 14] and enzymes associated with cell proliferation [15] such as ornithine decarboxylase [16, 17] and the braintype isoenzyme of creatine kinase (CK) [13, 14] .
PTH also causes increased proliferation of thymus, bone marrow and liver in vivo [18] , increases which are mediated by changes in Ca2l and/or cyclic AMP concentrations, in a variety of cell culture systems [8, 17] . As well as increasing adenylate cyclase activity [19] , PTH increases the proliferation [13, 14] of cultured bone cells, osteosarcoma cells and chondroprogenitor cells [20] . PTH was also shown to modulate phospholipid metabolism [21] . It promotes bone formation at low doses in vivo [22] [23] [24] , in addition to its effects on resorption; the net effect of the hormone on bone mass must, therefore, be determined by the balance between these two processes [25, 26] . Using histological techniques, it was found that there was an increase in the bone apposition rate, accompanied by an increase in the formation surface, without any increase in the resorption surface, after daily injection of PTH-(1-84) into rats [27] . Moreover, bovine (b)PTH-(1-34) was shown to have anabolic activity [28] which did not depend on early stimulation of resorption [29] . Indeed, it has been shown that PTH, together with vitamin D3, can be used at low doses for treatment of osteoporosis [30] . Moreover, increased bone formation in hyperparathyroid states in man [31] and animals [23, 24] has also been demonstrated. Recently we have shown that the central portion of the PTH molecule increases cell proliferation in chondrocytes [32] and in osteoblasts [33] without affecting cyclic AMP production. Therefore it was important to determine whether these fragments from the mid region of the PTH molecule can induce proliferation of bone cells in vivo and thus have the potential to be used to increase bone formation in pathological conditions such as osteoporosis.
MATERIALS AND METHODS

Animals
Batches of female (20-25- 13HlThymidine incorporation into DNA At 0, 2, 14 and 22 h after injection, the rats were killed and the tissues were removed rapidly, washed and cut into cubes, approx. 2 mm per side, which were found to give optimal incorporation. The pieces were then incubated for 2 h more (the time indicated in Fig. 6 ) with [3H]thymidine (5 ,Ci/ml; 5 Ci/mmol) at 37 'C in Dulbecco's modified Eagle's medium under an atmosphere of 50% C02/95 % air. Total [3H]thymidine uptake and incorporation into trichloroacetic acid-insoluble material was measured as described previously [36] . At no time, including the 22-24 h pulse, was there any significant change in the total uptake of [3H]thymidine which reflects changes in the thymidine pool which, in turn, could account for changes in incorporation. DNA was determined by the Burton method [37] .
Serum Ca2+ determination
Blood was withdrawn from the hearts of C02-anaesthetized rats 24 h after injection ofPTH fragments. The Ca2+ concentration in the serum was measured using an autoanalyser. The values obtained after injection of distilled water (0.121 + 0.004 mg/ml; mean + S.E.M.), hPTH-(1-34) (0.117 + 0.005 mg/ml) and hPTH-(28-48) (0.125 + 0.001 mg/ml) were not significantly different from each other.
Reagents
All reagents used were analytical grade. Biochemicals were obtained from Sigma (St. Louis, MO, U.S.A.). hPTH- (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) and hPTH-(34-47) were synthesized at the Gesellschaft fur Biotechnologische Forschung, Braunschweig, Germany.
Statistical significance
The significance of differences between experimental and control values was evaluated by Student's t test. (Fig. 1) . This increase persisted after 4 h and reached a maximum of approx. 2-fold at 24 h in diaphysis and epiphysis; in kidney at 24 h the activity had dropped to a level insignificantly greater than that at zero time. Injection with 2,g of bPTH-(1-34)/rat, equivalent to 13 nm, caused a similar increase in CK specific activity (Fig. 2) ; namely, significant increases at all three times measured in the diaphysis and epiphysis, and at 1 and 24 h in kidney. The mid-portion fragment hPTH-(28-48), which has mitogenic activity in vitro [32, 33] , also increased CK activity after injection of 1.25 ,ug/rat, equivalent to 14 nm (Fig. 3) . In kidney, CK specific activity increased to a peak between 1 and 4 h and then declined to close to the constitutive activity at 24 h. In the epiphysis there was a significant increase at 1 h, a maximal increase at 4 h and no significant increase at 24 h. However, in the diaphysis, CK activity was significantly increased at all three times measured, with the maximal increase at 1 h. Injection of rats with increasing doses of PTH-(1-34) caused a significant increase in CK specific activity 4 h later in all organs at the lowest dose tested (0.4,ug/rat) to a maximal value at 2,ug/rat, equivalent (Fig. 4) . When rats were injected with hPTH-(28-48) and killed 4 h later, a similar result was obtained (Fig. 5) ; there was a significant increase in CK specific activity in all three organs at a dose of 0.15,ug/rat, with a maximum effect at 1.25 ,g/rat (equivalent to 14 nM), which reached an approx. 3-fold stimulation in diaphysis.
RESULTS
Time
Comparison of effects of defined PTH fragments on CK activity and DNA synthesis in rat organs
To compare the activity of PTH-(28-48) ( Fig. 5) with that of other fragments derived from the mid region of PTH, rats were injected with hPTH-(25-39) or hPTH-(34-47) at a dose of 0.875 ,g/rat, equivalent to 14 nM; whereas hPTH-(25-39) caused a significant increase in CK activity, hPTH-(34-47) had no effect (Table 1) .
To corroborate that under the circumstances of these experiments the increase in CK specific activity in bone is indeed a valid marker of cell proliferation, changes in DNA synthesis were measured by [3H]thymidine incorporation [33] . The earliest time at which PTH increased [3H]thymidine incorporation was determined by injecting rats with an optimal dose of 2,ug of PTH-(1-34)/rat, equivalent to 13 nm (Fig. 4) , and measuring 2 h pulses of [3H]thymidine incorporation into DNA (Fig. 6 ). In the kidney, unlike the increase in CK activity, there was no increase in DNA synthesis at any time. In the diaphysis and the epiphysis there was no change at 4 or 16 h, but at 24 h there was a significant increase in DNA synthesis (Fig. 6) 
DISCUSSION
The results presented in this paper demonstrate that the midregion fragments hPTH-(25-39) and hPTH-(28-48), as well as the full-length bPTH-(1-84), stimulate DNA synthesis in rat diaphysis and epiphysis, and CK activity in diaphysis, epiphysis and kidney. The increases are dose-and time-dependent, as shown previously using in vitro models of chondrocytes [32] and both osteoblast-enriched calvaria cell cultures and ROS 17/2.8 osteoblast-like cells [33] . These results are in accord with data in vivo for stimulation of proliferation by bPTH-(1-84) and bPTH-(1-34) in ovariectomized rats [38] and intact rats [30, 38, 39] , dogs [4] and humans [30] . The fact that the mid-region fragments hPTH-(28-48) and hPTH-(25-39) can induce bone cell proliferation is of particular interest, since they do not stimulate cyclic AMP formation [32, 33] , which serves as an intracellular messenger for the osteolytic response to PTH [40] . This makes them potentially capable of promoting bone formation without At 4 h later, rats were killed and extracts were prepared and assayed as described in the Materials and methods section. Experimental details are as described for Fig. 1. (a) Diaphysis, (b) epiphysis, (c) kidney. *P < 0.05, **P < 0.01 versus controls. bone resorption. Moreover, in vitro [33] , hPTH-(28-48) was shown to inhibit cyclic AMP formation by bPTH-(1-84), which may further influence the equilibrium of bone turnover in the direction of formation rather than resorption. It will be of great interest to determine if fragments containing the mitogenic mid region of the PTH molecule are indeed produced and circulate in vivo.
The mid-region fragment hPTH-(28-48), which we utilized in this study, was originally intended as a competitive inhibitor of the cleavage of hPTH-(1-84), since it contained the major cleavage sites between residues 33 and 34 and residues 37 and 38 [41] . However, the stability of the fragment was shown by the present study to be sufficient to allow it to act as a mitogen after a single i.p. injection. The similarity between these studies in vivo and previous reports in vitro [32, 33] is encouraging, since it has often been pointed out (e.g. [19] ) that discrepancies between bioassays in vitro and in vivo make studies in vivo essential at an early stage of investigation.
The possibility of using a mid-region fragment of PTH to prevent bone loss in osteoporosis is strengthened by the recent finding [29] that resorption is not needed for stimulation of bone growth in living rats. In the present study, no significant change in serum calcium concentration was seen by 24 h after injection of a mitogenic dose of hPTH-(28-48). However, the time period and in such special cases as the specific inhibition of osteoblast production during space flight ( [44] and references therein).
